LENZ Therapeutics, Inc. Q1 FY2025 earnings call

• The first quarter of 2025 was productive, with the PDUFA target for LNZ100 just 3 months away. The Commercial Day event in April was successful, with positive feedback on commercial readiness. - Key takeaways from the Commercial Day included eye care professionals' enthusiasm for LNZ100's potential, progress in launch preparation across three pillars (doctors to recommend, patients to request, seamless access), and the sales force build-out with over 40% of the team accepting offers. - The company has a strong financial foundation with ~$194.1M in cash and upwardly revised cash at PDUFA to over $185M. - CLARITY study results showed high patient satisfaction with LNZ100, positioning it well for the market.

In the first quarter of 2025, total operating expenses increased to $16.9 million, an 11% increase from Q4 2024 but within operating plan. SG&A expenses for Q1 2025 were $11.3 million, up from $5.6 million in the same period in 2024, driven by increasing commercial headcount and prelaunch activities. R&D expenses decreased to $5.8 million in Q1 2025 from $10.5 million in the same period in 2024. The net loss in Q1 2025 was $14.6 million, with a net loss per share of $0.53. The company had approximately $194.1 million in cash, cash equivalents, and marketable securities at the end of Q1 2025.

• The company upwardly revised projected cash at PDUFA from over $170 million to over $185 million. - The cash runway is expected to fund the company's operations until post-launch positive operating cash flow. - The company will continue to be disciplined in spending as it approaches the August 8 PDUFA date.

• Recession risk and its potential impact on consumer sentiment, though the company sees medical aesthetics and beauty categories as somewhat insulated. - Regulatory and market risks related to product launch and competition, including potential prescribers suggesting alternative approved eye drops before LNZ100's approval.

Q: Stacy Ku asks about sample distribution, conversion rate from sample to paid prescription, and metrics; A: Shawn Olsson and Marc Odrich respond, mentioning sample distribution plans, training for sales team, and metrics like new script rates and refills.

Q: Pawan Patel asks about sample pack management, inventory levels, and e-pharmacy partnership; A: Shawn Olsson and Eef Schimmelpennink respond, discussing sample distribution tracking, inventory confidence, and e-pharmacy selection criteria.

Q: Yigal Nochomovitz asks about marketing plans, commercial model, and breakeven; A: Shawn Olsson and Eef Schimmelpennink respond, talking about influencer campaign timing, commercial model focus, and not guiding on revenue yet.

Q: Lachlan Hanbury-Brown asks about DTC marketing transition and sales force interactions pre-approval; A: Shawn Olsson responds, discussing unbranded to branded campaign transition and sales force pre-approval interactions.

Q: Denis Reznik asks about patents, e-pharmacy selection, and recession impact; A: Eef Schimmelpennink, Shawn Olsson, and Dan Chevallard respond, talking about patent protection, e-pharmacy selection factors, and recession impact considerations.

Q: Matthew Caufield asks about prescribers suggesting alternative approved eye drops; A: Eef Schimmelpennink and Shawn Olsson respond, emphasizing LNZ100's effectiveness and sampling as key factors.